We presented our pioneering DCT with RedHill Biopharma in front of 500+ senior executives from big pharma – offering a roadmap to at-home monitoring of infectious disease. By pairing FDA-approved devices with our patient-friendly virtual study platform and app, we’ve enabled remote monitoring of patient vitals formerly confined to the lab or clinic. Since most COVID-19 patients are recovering from illness at home, we’ve brought the research setting to them. Our presentation highlights the study design of this groundbreaking remote clinical trial.
Interested in Viewing the Webinar?
Fill out the form below for access.
ObvioHealth studies are run on our purpose-built platform by our own in-house virtual team. This allows us to work seamlessly from protocol design all the way through to analysis and reporting.
Up to 4x
3 mo ObvioHealth average vs 12 mo benchmark for site-based trials
average retention vs. 70% benchmark for traditional trials
average per study (digital questionnaires, daily ediary, etc.).